AstraZeneca Results Presentation Deck

Double-digit growth in US, Emerging Market, EU H1 Total Revenues (USD millions) and Growth vs PY +16% 9,081 US +22% Strong ex-COVID-19 growth across regions, disease areas Ex-China: 3,031 +38% China: 3,043 +9% Emerging Markets +13% CEO Opening Remarks 4,373 Europe +8% 2,450 Established Rest of World Financial Results 6 All growth rates at CER. Due to rounding, the sum of a number of dollar values and percentages may not agree to totals. Total Revenue and growth rates by region reflect ex-COVID-19 figures. Oncology +22% 8,794 Double-digit growth across Oncology, CVRM, R&I and Rare disease H1 Total Revenues (USD millions) and Growth vs PY Oncology +20% BioPharmaceuticals 5,239 CVRM +10% Rare Disease 3,180 R&I +12% CEO Closing Remarks 3,819 Rare Disease -76% 632 V&I

View entire presentation